

## Scottish International Conference on Multidisciplinary Research and Innovation – SICMRI 2026

### HYPERURICEMIA IN THE PROGRESSION OF CHRONIC KIDNEY DISEASE

**Karimova Muyassar Qobuljonovna**

*Samarkand State Medical University*

**Narziyev Komronbek Chori o'g'li**

*Samarkand State Medical University*

**Sayfiyeva Shirinbonu Faruxovna**

*Samarkand State Medical University*

**Azimova Aziza Azimovna**

*Samarkand State Medical University, Master's Degree in Therapeutic Medicine*

**Annotation:** Hyperuricemia is increasingly recognized as a significant factor in the progression of chronic kidney disease. Elevated uric acid levels contribute to renal injury through mechanisms such as inflammation, oxidative stress, endothelial dysfunction, and activation of harmful hormonal pathways. Clinical studies indicate that persistent hyperuricemia accelerates the decline in kidney function and increases the risk of end-stage renal disease. Early identification and management of hyperuricemia, including lifestyle modification and pharmacological therapy, can slow disease progression and improve patient outcomes. Understanding the role of uric acid in kidney disease is essential for developing effective prevention and treatment strategies.

**Keywords:** Hyperuricemia, Chronic kidney disease, Renal function, Uric acid, Inflammation, Oxidative stress, Endothelial dysfunction.

#### Introduction

Chronic kidney disease is a global health problem characterized by the gradual loss of kidney function over time. Among the metabolic disorders associated with kidney disease, high uric acid levels in the blood have attracted attention as a factor that may not only result from kidney dysfunction but also contribute to its progression. Uric acid is a product of purine metabolism and can cause damage to blood vessels, inflammation, and oxidative stress, which worsen kidney injury. Research indicates that persistent high uric acid levels can accelerate damage to kidney structures, leading to faster decline in kidney function. Studying the role of high uric acid in kidney disease is important for developing treatments that can slow disease progression and improve patient health outcomes.

#### Relevance

High uric acid levels contribute to kidney damage by causing inflammation and oxidative stress. Addressing hyperuricemia is important to slow the progression of chronic kidney disease and improve patient outcomes.

#### Main part

Hyperuricemia refers to an abnormally high level of uric acid in the blood. Uric acid is the final product of purine metabolism in humans. Normally, uric acid is excreted by the kidneys, but impaired renal function can lead to its accumulation. Factors contributing to hyperuricemia include high dietary intake of purine-rich foods, excessive fructose consumption, obesity,

## Scottish International Conference on Multidisciplinary Research and Innovation – SICMRI 2026

hypertension, and genetic predisposition. In chronic kidney disease, decreased glomerular filtration and tubular secretion reduce uric acid excretion, creating a vicious cycle of accumulation. Uric acid has multiple biological effects that can damage the kidneys. It can induce oxidative stress by increasing reactive oxygen species production. It also promotes inflammation through activation of pro-inflammatory pathways such as nuclear factor-kappa B. Hyperuricemia can lead to endothelial dysfunction by impairing nitric oxide availability, which is critical for vascular health. Additionally, uric acid can stimulate the renin-angiotensin-aldosterone system, resulting in elevated blood pressure and further renal injury. Crystal-independent mechanisms, such as intracellular uric acid effects on renal cells, also contribute to glomerular and tubular damage. Animal and human studies have shown that persistent hyperuricemia accelerates kidney fibrosis and proteinuria development. Understanding these mechanisms is essential for identifying therapeutic targets. Management strategies include lifestyle modifications, dietary control, and pharmacological treatment to lower uric acid levels. Early intervention may prevent progression of chronic kidney disease and reduce cardiovascular risks. Overall, hyperuricemia plays a dual role as both a marker and mediator of renal injury.

Multiple clinical studies have established a strong association between high uric acid levels and kidney function decline. Observational studies show that patients with elevated uric acid have faster progression to advanced stages of chronic kidney disease. Epidemiological data suggest that hyperuricemia is an independent risk factor for developing end-stage renal disease. Longitudinal studies demonstrate that even mildly elevated uric acid can predict future decline in glomerular filtration rate. Patients with both hyperuricemia and hypertension have particularly rapid kidney function deterioration. Interventional studies using uric acid-lowering drugs, such as allopurinol or febuxostat, have shown slowing of chronic kidney disease progression in selected populations. These drugs reduce proteinuria, improve endothelial function, and decrease inflammatory markers. Meta-analyses confirm that controlling uric acid may delay the need for dialysis. However, some studies report conflicting results, indicating that hyperuricemia may act as a marker rather than a direct cause in certain patients. The variability may depend on underlying comorbidities, genetic factors, and baseline kidney function. Consistent monitoring of serum uric acid is therefore recommended in chronic kidney disease management. Early identification and treatment of hyperuricemia can provide a window of opportunity to slow renal deterioration. Integrating uric acid control into routine nephrology practice may improve long-term patient outcomes. Understanding clinical evidence helps guide personalized interventions.

Management of hyperuricemia aims to reduce uric acid levels and limit kidney damage. Non-pharmacological interventions include dietary modification, weight control, limiting alcohol intake, and reducing consumption of high-purine foods. Adequate hydration is recommended to facilitate uric acid excretion. Pharmacological therapy is indicated when lifestyle measures are insufficient or uric acid levels are persistently high. Xanthine oxidase inhibitors, such as allopurinol and febuxostat, reduce uric acid production and are widely used in patients with chronic kidney disease. Dose adjustments are required according to renal function to avoid drug toxicity. Uricosuric agents, which increase renal excretion of uric acid, can be considered in selected patients with preserved kidney function. Combination therapy may be necessary in refractory cases. Emerging therapies targeting uric acid metabolism and inflammation are under investigation. Regular monitoring of uric acid levels and kidney function is essential to assess therapeutic effectiveness and prevent adverse effects. Early and sustained uric acid control may reduce proteinuria, delay progression to advanced kidney disease, and lower cardiovascular risks. Patient education about the importance of adherence to therapy is crucial. Multidisciplinary care, involving nephrologists, dietitians, and primary care providers, optimizes outcomes. Overall, effective management of hyperuricemia represents a key strategy in slowing chronic kidney disease progression and improving quality of life for patients.

## Scottish International Conference on Multidisciplinary Research and Innovation – SICMRI 2026

### Conclusion

Hyperuricemia plays a significant role in the progression of chronic kidney disease by promoting inflammation, oxidative stress, endothelial dysfunction, and activation of harmful hormonal pathways. Clinical evidence indicates that elevated uric acid levels are associated with faster decline in kidney function and higher risk of end-stage renal disease. Early identification and effective management of hyperuricemia, through lifestyle modifications and pharmacological therapy, can slow renal deterioration, reduce complications, and improve patient outcomes. Therefore, controlling uric acid levels represents a crucial strategy in the prevention and treatment of chronic kidney disease progression.

### References

1. Johnson, R. J., Nakagawa, T., Sanchez-Lozada, L. G., Shafiu, M., Sundaram, S., Le, M., ... & Kang, D. H. (2013). Uric acid and chronic kidney disease: which is cause and which is effect? *Nephrology Dialysis Transplantation*, 28(9), 2221–2228.
2. Takata, T., Mae, Y., Hoi, S., Iyama, T., & Isomoto, H. (2025). Hyperuricemia in chronic kidney disease: Emerging pathophysiology and a novel therapeutic strategy. *International Journal of Molecular Sciences*, 26(18).
3. Nabi, A., Ismail, M., & Rehman, W. (2025). Association between hyperuricemia and progression of chronic kidney disease: A longitudinal study. *Journal of Pak International Medical College*, 1(1).
4. Wang, X., Li, Y., Chen, Z., & Zhang, Q. (2024). Effects of uric acid-lowering therapy on renal outcomes in CKD patients with asymptomatic hyperuricemia: A systematic review and meta-analysis. *BMC Nephrology*.
5. Yang, H., Ying, J., Zu, T., Meng, X.-M., & Jin, J. (2024). Insights into renal damage in hyperuricemia: Focus on renal protection. *Molecular Medicine Reports*, 31(3), 59.